$801 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 13 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PMVP | PMV PHARMACEUTICALS INC | $397,964,000 | +73.3% | 6,469,911 | 0.0% | 49.71% | -25.0% | |
| AI | New | C3.AI | $240,519,000 | – | 1,733,467 | +100.0% | 30.04% | – |
| REAL | THE REALREAL | $75,309,000 | +35.0% | 3,854,080 | 0.0% | 9.41% | -41.6% | |
| GKOS | GLAUKOS CORP | $48,646,000 | +52.0% | 646,364 | 0.0% | 6.08% | -34.2% | |
| STIM | Sell | NEURONETICS INC | $11,047,000 | +120.5% | 994,315 | -3.5% | 1.38% | -4.5% |
| EIGR | EIGER BIOPHARMACEUTICALS INC | $9,401,000 | +51.0% | 764,918 | 0.0% | 1.17% | -34.7% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $7,383,000 | +50.8% | 388,766 | 0.0% | 0.92% | -34.7% | |
| AGTC | Sell | APPLIED GENETIC TECHNOL CORP | $5,744,000 | -18.8% | 1,404,515 | -3.5% | 0.72% | -64.9% |
| CDTX | CIDARA THERAPEUTICS INC | $2,714,000 | -29.8% | 1,356,813 | 0.0% | 0.34% | -69.6% | |
| VERO | VENUS CONCEPT INC | $1,139,000 | -25.5% | 658,657 | 0.0% | 0.14% | -67.8% | |
| OBALON THERAPEUTICS INC | $570,000 | +64.7% | 380,224 | 0.0% | 0.07% | -29.0% | ||
| XENE | XENON PHARMACEUTICALS INC | $128,000 | +39.1% | 8,293 | 0.0% | 0.02% | -40.7% | |
| DARE | DARE BIOSCIENCE INC | $67,000 | +34.0% | 50,368 | 0.0% | 0.01% | -42.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-01-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLAUKOS CORP | 28 | Q3 2023 | 33.0% |
| EIGER BIOPHARMACEUTICALS INC | 24 | Q3 2022 | 17.7% |
| APPLIED GENETIC TECHNOL CORP | 24 | Q3 2022 | 6.7% |
| XENON PHARMACEUTICALS INC | 20 | Q3 2021 | 0.6% |
| CIDARA THERAPEUTICS INC | 19 | Q2 2021 | 4.5% |
| THE REALREAL | 18 | Q3 2023 | 62.6% |
| KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 10.8% |
| DARE BIOSCIENCE INC | 16 | Q3 2023 | 0.3% |
| MACROGENICS INC | 14 | Q1 2020 | 19.2% |
| PMV PHARMACEUTICALS INC | 13 | Q3 2023 | 67.5% |
View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-02-27 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-07-21 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-04-13 |
| 13F-HR | 2022-01-25 |
| 13F-HR | 2021-10-19 |
View INTERWEST VENTURE MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.